New progress in cardiac surgery

Home > Archive>Volume 28, Issue 10, 2020 >829-832

New progress in cardiac surgery
DOI:
                        
                    
CSTR:
                        
                    
Author:
                        OU JingSong1,2OU JingSong
Division of Cardiac Surgery, Heart Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China;National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases & NHC key Laboratory of Assisted Circulation Sun Yat-sen University & Guangdong Provincial Engineering and Technology Center for Diagnosis and Treatment of Vascular Diseases & Guangdong Provincial Key Laboratory of Brain Function and Disease, Guangzhou, Guangdong 510080, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:1.Division of Cardiac Surgery, Heart Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China;2.National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases & NHC key Laboratory of Assisted Circulation (Sun Yat-sen University) & Guangdong Provincial Engineering and Technology Center for Diagnosis and Treatment of Vascular Diseases & Guangdong Provincial Key Laboratory of Brain Function and Disease, Guangzhou, Guangdong 510080, China)
Clc Number:R6
Fund Project:

Article

Figures

Metrics

Reference [41]

Cited by

Materials

Comments

Abstract:

With the development of science and technology, there are many new developments in the field of cardiovascular surgery. The section of cardiovascular surgery in this issue focuses on the new methods of cardiovascular surgery, factors affecting cardiovascular surgery outcome, perioperative cardiovascular protection and changes in lipoproteins’ function of cardiovascular diseases.

Key words:cardiac surgery; surgery; perioperative period; cadiovascular protection

Reference

[1] Uehara K, Minakata K, Saito N, et al.Use of extracorporeal membrane oxygenation in complicated transcatheter aortic valve replacement.Gen Thorac Cardiovasc Surg, 7,5(6):329-336.

[2] Trenkwalder T, Pellegrini C, Holzamer A, et al.Emergency extracorporeal membrane oxygenation in transcatheter aortic valve implantation:A two-center experience of incidence, outcome and temporal trends from 2010 to 2015.Catheter Cardiovasc Interv, 8,2(1):149-156.

[3] 金屏, 刘洋, 郭红, 等.3D打印模型评估在ECMO辅助TAVR手术治疗主动脉瓣狭窄10例应用研究.中国动脉硬化杂志, 0,8(10):841-846.

[4] 胡盛寿, 高润霖, 刘力生, 等.《中国心血管病报告2018》概要.中国循环杂志, 9,4(3):209-220.

[5] 席悦, 王晰朦, 刘健, 等.影响冠状动脉旁路移植术患者近期预后的因素分析.中国动脉硬化杂志, 0,8(10):852-855.

[6] 何奔, 韩雅玲.中国ST段抬高型心肌梗死救治现状及应有对策.中华心血管病杂志, 9,7(2):82-84.

[7] 王海龙, 王卓众, 田进伟, 等.前降支或非前降支ST抬高型心梗患者射血分数低的危险因素及预后.中国动脉硬化杂志, 0,8(10):833-840.

[8] Gupta N, Li W, Willard B, et al.Proteasome proteolysis supports stimulated platelet function and thrombosis.Arterioscler Thromb Vasc Biol, 4,4(1):160-168.

[9] Buendía P, Montes De Oca A, Madueo JA, et al.Endothelial microparticles mediate inflammation-induced vascular calcification.FASEB J, 5,9(1):173-181.

[10] Sansone R, Stanske B, Keymel S, et al.Macrovascular and microvascular function after implantation of left ventricular assist devices in end-stage heart failure:Role of microparticles.J Heart Lung Transplant, 5,4(7):921-932.

[11] Mahmoud AM, Wilkinson FL, McCarthy EM, et al.Endothelial microparticles prevent lipid-induced endothelial damage via Akt/enos signaling and reduced oxidative stress.FASEB J, 7,1(10):4636-4648.

[12] Sódar BW, Kovács , Visnovitz T, et al.Best practice of identification and proteomic analysis of extracellular vesicles in human health and disease.Expert Rev Proteomics, 7,4(12):1073-1090.

[13] Panfoli I, Santucci L, Bruschi M, et al.Microvesicles as promising biological tools for diagnosis and therapy.Expert Rev Proteomics, 8,5(10):801-808.

[14] Chen IH, Xue L, Hsu CC, et al.Phosphoproteins in extracellular vesicles as candidate markers for breast cancer.Proc Natl Acad Sci USA, 7,4(12):3175-3180.

[15] Fu L, Hu XX, Lin ZB, et al.Circulating microparticles from patients with valvular heart disease and cardiac surgery inhibit endothelium-dependent vasodilation.J Thorac Cardiovasc Surg, 5,0(3):666-672.

[16] Lin ZB, Ci HB, Li Y, et al.Endothelial microparticles are increased in congenital heart diseases and contribute to endothelial dysfunction.J Transl Med, 7,5(1):4.

[17] Jian YP, Yuan HX, Hu KH, et al.Protein compositions changes of circulating microparticles in patients with valvular heart disease subjected to cardiac surgery contribute to systemic inflammatory response and disorder of coagulation.Shock, 9,2(5):487-496.

[18] 马建, 陈雅婷, 陈超, 等.体外循环心脏手术后不同粒径循环微粒浓度与正性肌力药物剂量相关性分析.中国动脉硬化杂志, 0,8(10):847-851.

[19] Chang FJ, Yuan HY, Hu XX, et al.High density lipoprotein from patients with valvular heart disease uncouples endothelial nitric oxide synthase.J Mol Cell Cardiol, 4,4:209-219.

[20] 区乐淳, 彭月明, 欧志君, 等.高密度脂蛋白功能对心血管疾病和围手术期心血管保护的影响.中国动脉硬化杂志, 0,8(10):856-860.

[21] Li ZH, Lv YB, Zhong WF, et al.High density lipoprotein cholesterol and all-cause and cause-specific mortality among the elderly.J Clin Endocrinol Metab, 9,4(8):3370-3378.

[22] Hamer M, O'Donovan G, Stamatakis E.High-density lipoprotein cholesterol and mortality:Too much of a good thing?.Arterioscler Thromb Vasc Biol, 8,8(3):669-672.

[23] Bowe B, Xie Y, Xian H, et al.High density lipoprotein cholesterol and the risk of all-cause mortality among U.S.Veterans.Clin J Am Soc Nephrol, 6,1(10):1784-1793.

[24] Ding D, Li X, Qiu J, et al.Serum lipids, apolipoproteins, and mortality among coronary artery disease patients.Biomed Res Int, 4,4:709756.

[25] Souza FR, Dos Santos MR, Porello RA, et al.Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users.Atherosclerosis, 9,3:100-105.

[26] Miki T, Miyoshi T, Kotani K, et al.Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification:Subanalysis of a prospective multicenter study.Atherosclerosis, 9,3:1-6.

[27] Samadi S, Mehramiz M, Kelesidis T, et al.High density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease:Results from mashad cohort.J Cell Physiol, 2019.DOI:10.1002/jcp.28276.

[28] Besler C, Heinrich K, Rohrer L, et al.Mechanisms underlying adverse effects of HDL on enos-activating pathways in patients with coronary artery disease.J Clin Invest, 1,1(7):2693-2708.

[29] Adams V, Besler C, Fischer T, et al.Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.Circ Res, 3,3(12):1345-1355.

[30] 欧志君, 常凤军, 胡晓侠, 等.高胆固醇血症病人的高密度脂蛋白损伤血管功能.中国动脉硬化杂志, 5,3(12):1192-1196.

[31] 李华明, 欧志君, 李艳, 等.高密度脂蛋白功能改变可能是动脉粥样硬化形成的危险因素.中国动脉硬化杂志, 5,3(12):1189-1191.

[32] Sviridov D, Chin-Dusting J, Nestel P, et al.Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients:Evidence for impaired reverse cholesterol transport.Transplantation, 6,1(3):361-366.

[33] Burillo E, Jorge I, Martínez-López D, et al.Quantitative HDL proteomics identifies peroxiredoxin-6 as a biomarker of human abdominal aortic aneurysm.Sci Rep, 6,6:38477.

[34] Martinez-Lopez D, Camafeita E, Cedo L, et al.Apoa1 oxidation is associated to dysfunctional high-density lipoproteins in human abdominal aortic aneurysm.E Bio Medicine, 9,3:43-53.

[35] Delbosc S, Rouer M, Alsac JM, et al.High-density lipoprotein therapy inhibits porphyromonas gingivalis-induced abdominal aortic aneurysm progression.Thromb Haemost, 6,5(4):789-799.

[36] Shao BH, Tang CR, Sinha A, et al.Humans with atherosclerosis have impaired abca1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase.Circ Res, 4,4(11):1733-1742.

[37] Hewing B, Parathath S, Barrett T, et al.Effects of native and myeloperoxidase-modified apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in mice.Arterioscler Thromb Vasc Biol, 4,4(4):779-789.

[38] Huang Y, Didonato JA, Levison BS, et al.An abundant dysfunctional apolipoprotein a1 in human atheroma.Nat Med, 4,0(2):193-203.

[39] Hacquebard M, Ducart A, Schmartz D, et al.Changes in plasma LDL and HDL composition in patients undergoing cardiac surgery.Lipids, 7,2(12):1143-1153.

[40] Ou J, Wang J, Xu H, et al.Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on western diet.Circ Res, 5,7(11):1190-1197.

[41] Sharma S, Umar S, Potus F, et al.Apolipoprotein A-I mimetic peptide 4f rescues pulmonary hypertension by inducing microrna-193-3p.Circulation, 4,0(9):776-785.

Get Citation

OU JingSong. New progress in cardiac surgery[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2020,28(10):829-832.

Copy

Article Metrics

Abstract:634
PDF: 815
HTML: 0
Cited by: 0

History

Received:April 20,2020
Revised:June 21,2020
Adopted:
Online: October 20,2020
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code